Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides Business Update

NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company bringing high-impact technologies to patients faster through risk-return sharing partnerships, today reported financial results for the second quarter of 2024 and provided a business update.

“Our work in hypertension and coronary artery disease aligns with a renaissance taking place in cardiac pacing and balloon angioplasty, where new innovations are being applied to improve these foundational device-based interventions and create more powerful therapeutic solutions. At our inaugural R&D Day in June, we were excited to share our insights into this renaissance and the potential role we believe our lead programs – AVIM Therapy and Virtue SAB – will play in improving patient outcomes. We were pleased to host respected cardiology leaders Drs. David Kandzari and Vivek Reddy, who highlighted the critical unmet needs in high-risk hypertension and expressed their excitement about the potential of AVIM Therapy to transform care for these patient populations,” said David Hochman, Founder, CEO and Chairman of Orchestra BioMed. “As we look ahead to the second half of the year, we remain focused on driving patient enrollment in the global pivotal BACKBEAT study in the US and EU, and look forward to providing important updates on our Virtue SAB program.”